Advertisement
Screener

Alkermes plc. (ALKS) Foreign Income Tax Expense (Benefit), Continuing Operations

2.8 / 5 stars · 68/120 Roast Me

Alkermes plc. Foreign Income Tax Expense (Benefit), Continuing Operations

Alkermes plc. (ALKS) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $4.40 million for the 3-month period ending 2012-12-31, per its 10-Q filed 2013-01-31.

Discontinued › Expense Statement › Income Tax

us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2013-01-31

  • Alkermes plc. foreign income tax expense (benefit), continuing operations for the quarter ending 2012-12-31 was $4.40M.
  • Alkermes plc. foreign income tax expense (benefit), continuing operations for the quarter ending 2012-09-30 was $400.00K.
  • Alkermes plc. foreign income tax expense (benefit), continuing operations for the quarter ending 2012-06-30 was $800.00K.
Period endForeign Income Tax Expense (Benefit), Continuing Operations 3 monthForeign Income Tax Expense (Benefit), Continuing Operations 6 monthForeign Income Tax Expense (Benefit), Continuing Operations 9 month
2012-12-31$4.40M
10-Q · filed 2013-01-31
$4.80M
derived: sum of 2 quarters · filed 2013-01-31
$5.60M
10-Q · filed 2013-01-31
2012-09-30$400.00K
10-Q · filed 2012-11-01
$1.20M
10-Q · filed 2012-11-01
2012-06-30$800.00K
10-Q · filed 2012-07-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76